MOVANO INC

Company Overview

Movano Inc. (MOV E) is a small, R&D- and IP-focused medical device/wearable company developing the Evie family of rings that bridge consumer wellness and medical-grade monitoring. Its Evie Ring launched DTC in November 2023 and the prescription EvieMED Ring received FDA 510(k) clearance for pulse oximetry in November 2024, enabling clinical, trial and provider channels while the company pursues a proprietary RF SoC for non‑invasive CGM and cuffless blood pressure. The company emphasizes clinical validation, multi‑antenna RF, ML/cloud analytics and a growing patent portfolio, but remains early-stage with limited revenue, concentrated operations (32 employees at 12/31/2024), meaningful regulatory and supply‑chain dependencies, and ongoing funding needs that raise going‑concern risk.

Executive Compensation Practices

Given Movano’s stage and filings, compensation will likely be equity‑heavy with meaningful stock‑based awards and milestone‑based long‑term incentives tied to FDA clearances, pivotal clinical results, manufacturing/SoC scale milestones and commercial adoption (Evie/EvieMED sales metrics or enterprise partnerships). Management already disclosed increased stock‑based compensation and the company has reduced cash payroll/marketing to conserve liquidity, suggesting a deliberate shift toward options/RSUs to preserve cash. Performance bonus structures and option vesting tied to clinical/regulatory events and partnership/commercial milestones are typical here; accounting for warrants and equity valuation will also materially affect reported compensation expense and dilution expectations.

Insider Trading Considerations

Insider trading at Movano will likely cluster around high‑impact events (FDA clearances, pivotal trial readouts, partnership announcements, financing closes or strategic‑alternatives updates), and the stock is prone to volatility from warrant remeasurements, ATM activity and financing news. Because the company faces near‑term funding pressure and has used equity compensation, insider sales may reflect personal liquidity needs or option exercise/dilution management rather than a pure signal of operational weakness; conversely, insider buys can be a stronger signal of confidence given illiquid cash position. Investors should watch for 10b5‑1 plan disclosures, Section 16 filings and blackout windows around clinical/financial disclosures, and be aware that Nasdaq delisting risk and confidentiality rules around clinical data add regulatory sensitivity to timing and permissibility of trades.